FPRX - Five Prime Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5193.66M
Enterprise Value 33.2M
Trailing P/E N/A
Forward P/E 1-1.76
PEG Ratio (5 yr expected) 10.02
Price/Sales (ttm)8.52
Price/Book (mrq)0.80
Enterprise Value/Revenue 30.14
Enterprise Value/EBITDA 6-0.02

Trading Information

Stock Price History

Beta (3Y Monthly) 1.32
52-Week Change 3-64.42%
S&P500 52-Week Change 34.88%
52 Week High 316.36
52 Week Low 35.32
50-Day Moving Average 36.03
200-Day Moving Average 39.95

Share Statistics

Avg Vol (3 month) 3496.94k
Avg Vol (10 day) 3360.46k
Shares Outstanding 536.06M
Float 28.66M
% Held by Insiders 13.28%
% Held by Institutions 188.24%
Shares Short (Jun 28, 2019) 41.16M
Short Ratio (Jun 28, 2019) 41.59
Short % of Float (Jun 28, 2019) 44.24%
Short % of Shares Outstanding (Jun 28, 2019) 43.21%
Shares Short (prior month May 31, 2019) 42.05M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019


Profit Margin 0.00%
Operating Margin (ttm)-702.75%

Management Effectiveness

Return on Assets (ttm)-26.53%
Return on Equity (ttm)-52.11%

Income Statement

Revenue (ttm)22.73M
Revenue Per Share (ttm)0.66
Quarterly Revenue Growth (yoy)-83.50%
Gross Profit (ttm)-106.48M
EBITDA -154.53M
Net Income Avi to Common (ttm)-155.44M
Diluted EPS (ttm)-4.49
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)236.96M
Total Cash Per Share (mrq)6.77
Total Debt (mrq)52.3M
Total Debt/Equity (mrq)22.32
Current Ratio (mrq)10.41
Book Value Per Share (mrq)6.73

Cash Flow Statement

Operating Cash Flow (ttm)-144.57M
Levered Free Cash Flow (ttm)-100.34M